Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Encouraging share price resilience

<< Previous

Bullboard Posts

Next >>

Post by westcoast1000on Dec 16, 2022 5:39pm

341 Views

Post# 35176985

Encouraging share price resilience

Echoing previous posts, the market activity is very encouraging. The share price is up 6.5 percent, and the volume is 30 percent above the 30 day average, in a very discouraged, risk off market clobbered by interest rates.

That means we have strong market support. Given the news and price, that is what I would expect, but then I have expected strong market support to appear for a long time. It has not been very evident until now.

<< Previous

Bullboard Posts

Next >>

Mining companies take action on reconciliation with First Nations